Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q3 2025 value amounting to $1000.0.

  • NovaBay Pharmaceuticals' Depreciation & Amortization (CF) changed 0.0% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20000.0, marking a year-over-year decrease of 3939.39%. This contributed to the annual value of $40000.0 for FY2024, which is 2156.86% down from last year.
  • NovaBay Pharmaceuticals' Depreciation & Amortization (CF) amounted to $1000.0 in Q3 2025, which was down 0.0% from $1000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $32000.0 for Q4 2022, and its period low was $1000.0 during Q3 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $14315.8, with a median of $13000.0 in 2021.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 23333.33% in 2022, then crashed by 9230.77% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Depreciation & Amortization (CF) stood at $27000.0 in 2021, then increased by 18.52% to $32000.0 in 2022, then plummeted by 62.5% to $12000.0 in 2023, then surged by 33.33% to $16000.0 in 2024, then plummeted by 93.75% to $1000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $1000.0 in Q3 2025, compared to $1000.0 in Q2 2025 and $2000.0 in Q1 2025.